Alginate Capsule with Zwitterionic Coating for Islet Transplantation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for type 1 diabetes, such as islet transplantation, face challenges including scarcity of organ sources, long-term loss of graft functionality, and the need for lifelong immunosuppression, while existing encapsulation methods struggle with inadequate oxygen and nutrient delivery to insulin-secreting cells, leading to limited functionality and increased risk of immune rejection.

Innovation Solution

Development of a capsule comprising alginate-encapsulated insulin-secreting cells, mesenchymal stem cells, and extracellular matrix, with a surface coated by a zwitterionic polymer like chitosan, designed to enhance oxygen and nutrient diffusion, reduce immune rejection, and promote vascularization, thereby maintaining insulin production and secretion without the need for immunosuppressive drugs.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If islet transplantation is performed, then endogenous glycemia regulation is achieved, but lifelong immunosuppression is required

Engineering Contradiction:
Improveglycemia regulationVSAvoidimmunosuppression requirements
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The islet transplantation approach is segmented into two distinct components: (1) the immunogenic islet cells that perform glycemia regulation, and (2) the biocompatible capsule that provides immune protection. This segmentation allows the islets to be isolated from the host immune system while maintaining their endocrine function, thereby achieving glycemia control without requiring lifelong immunosuppression.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

A biocompatible capsule acts as an intermediary barrier between the transplanted islets and the host immune system. This capsule mediates the interaction by physically separating the immunogenic cells from immune cells while still permitting the passage of nutrients, oxygen, and insulin, thus protecting the islets from immune rejection without compromising their regulatory function.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If encapsulation is used to avoid immunosuppression, then immune protection is provided, but oxygen and nutrient delivery becomes inadequate

Engineering Contradiction:
Improveimmune rejectionVSAvoidoxygen and nutrient delivery
Core Design Contradiction:
Object-affected harmful factorsVSQuantity of substance

Solution Approach 1:

The biocompatible capsule is designed with a porous structure that allows selective diffusion of substances. The porosity enables adequate delivery of oxygen and nutrients to the encapsulated islets while simultaneously preventing the infiltration of immune cells, thus resolving the contradiction between immune protection and metabolic support.

Inventive Principle:
Principle #31Porous materials

Solution Approach 2:

The physical and chemical parameters of the capsule material are optimized to achieve the desired balance. By adjusting parameters such as pore size, porosity, and material composition, the capsule permits sufficient diffusion of small molecules (oxygen, nutrients, insulin) while blocking larger immune cells, thereby maintaining both immune protection and metabolic viability.

Inventive Principle:
Principle #35Parameter changes

3Ease of manufacture

If simple alginate encapsulation is used, then rapid gelling is achieved, but cell functionality is limited

Engineering Contradiction:
Improvegelling speedVSAvoidcell functionality
Core Design Contradiction:
Ease of manufactureVSReliability

Solution Approach 1:

The capsule is constructed using composite materials that combine the rapid gelling properties of alginate with additional biocompatible materials that enhance cell functionality. This composite structure maintains the ease of manufacture provided by alginate's rapid gelling while adding functional properties such as improved porosity, mechanical strength, and biochemical cues that support islet viability and insulin secretion.

Inventive Principle:
Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The capsule design improves the viability and functionality of insulin-secreting cells, allowing for sustained insulin production and reduced immune rejection, potentially providing a year or more of insulin-free treatment with minimal adverse effects.

Implementation Method 1

the surface of the capsule is at least partly coated with a zwitterionic polymer

Methodology Applied
Scientific EffectZwitterionic polymer coating: Coatings

Implementation Method 2

zwitterionic polymers have the ability to interact with the surrounding environment through steric repulsion and electrostatic interactions, thereby preventing the adsorption of proteins and other biomolecules

Methodology Applied
Scientific EffectSteric repulsion:

Implementation Method 3

allowing for sustained insulin production and reduced immune rejection

Methodology Applied
Scientific EffectDiffusion: Diffusion

Implementation Method 4

zwitterionic polymers have the ability to interact with the surrounding environment through steric repulsion and electrostatic interactions

Methodology Applied
Scientific EffectElectrostatic interactions:

Implementation Method 5

When used in vivo, the material used for the composition of the capsule should be biocompatible

Methodology Applied
Scientific EffectBiocompatibility:

Data Source

PatentEP3946254B1Capsule comprising insulin-secreting cells for treating diabetes
Publication Date: 2024.06.12 ESTAB FR DU SANG
  • EP3946254B1 patent drawingFigure 1
  • EP3946254B1 patent drawingFigure 2~3

AI summary

The application concerns a capsule comprising alginate encapsulating: - insulin-secreting cells, - a RGD-alginate, - mesenchymal stem cells, - extracellular matrix, the process for the preparation thereof and the use thereof for treating diabetes.